GenFleet to Unveil Early Clinical Results for KRAS G12D Inhibitor GFH375 and Pan-RAS Candidate GFH276; Investor Calls and ESMO Late-Breaking Abstract Confirmed

Bulletin Express09-23

GenFleet Therapeutics (Shanghai) Inc. (GENFLEET-B) has outlined a detailed timetable for the first public release of clinical data from two of its lead RAS pathway assets, GFH375 and GFH276.

GFH375 DISCLOSURE PLAN • Preliminary data from the Phase I combination study of GFH375—an investigational KRAS G12D inhibitor—plus cetuximab in KRAS G12D-mutant solid tumors will be presented via an online investor call on 15 October 2026 (Beijing time). • Verastem Oncology, GenFleet’s ex-China development and commercialization partner for GFH375 (VS-7375), will host a separate investor call on 14 October 2026 to discuss overseas progress.

GFH276 DISCLOSURE PLAN • Initial results from a Phase I monotherapy study of GFH276, an oral pan-RAS inhibitor leveraging a CypA-RAS tri-complex mechanism, have been selected as Late-Breaking Abstract LBA33 for oral presentation at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid. • The presentation is scheduled for 25 October 2026, 08:30–10:00 local time in the Development Therapeutic Session. • GenFleet will conduct an investor call on the same day to provide further interpretation of the on-site data.

STRATEGIC CONTEXT GenFleet’s RAS/MAPK collaboration with Verastem grants the US partner an exclusive option to license three discovery-stage oncology programs outside China upon achievement of predefined Phase I milestones. Verastem designated GFH375/VS-7375 as the lead asset in December 2023 and exercised its license option in January 2025. GenFleet retains China rights to all partnered assets.

PRODUCT PROFILES • GFH375 (VS-7375): Small-molecule inhibitor targeting KRAS G12D mutations; currently evaluated in combination with cetuximab for solid tumors harboring KRAS G12D alterations. • GFH276: First-in-class oral pan-RAS (ON) inhibitor designed to bind active RAS proteins across KRAS, NRAS and HRAS variants, including common mutations such as G12C, G12D and G12V.

REGULATORY NOTE Pursuant to Hong Kong Listing Rule 18A.05, GenFleet cautions that successful development and commercialization of GFH375 and GFH276 are not guaranteed. Investors are urged to exercise caution when trading the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment